Endo Partners With US Government On Critical Medicines
Par Unit Will Expand Sterile Fill-Finish Manufacturing Capacity At Its Rochester Facility
Executive Summary
Endo subsidiary Par Sterile Products will expand its Rochester, Michigan facility to begin the fill-finish manufacturing of both mRNA and adenovirus vaccines. Around three-quarters of the project’s expected $120m total costs are being funded by the US government as part of larger efforts to boost the country’s domestic supply of essential medicines.
You may also be interested in...
Endo Counts On Vasostrict Revenues Despite Competition
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
Generics Industry At The Forefront In War Against COVID-19 In 2021
As the COVID-19 pandemic continued in 2021, the off-patent industry stepped in to provide relief in a variety of ways, whether through securing supplies of essential medicines or helping to manufacture and distribute newly-developed treatments.
US Bill Would Create Emergency API Stockpile
US representatives Abigail Spanberger and David McKinley have introduced bipartisan legislation to create an emergency supply of active ingredients used in vital generics and to incentivize domestic manufacturing of these ingredients. The move has garnered support from many industry leaders.